Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adagrasib + TNO155 in KRAS G12C Advanced Solid Tumors
NCT04330664Phase 1Completed
- Sponsor
- Mirati Therapeutics
- Start
- Apr 2020
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of adagrasib and batoprotafib in solid tumor (advanced stage) (3 arms), sponsored by Mirati Therapeutics. Primary endpoints: Safety and Tolerability (AEs, SAEs) at 20 months and Pharmacokinetics at 20 months. Started Apr 2020; status: completed.
02
Drugs
adagrasibbatoprotafib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04330664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04330664.